BioSpace News Archive

Eurofins DiscoverX, the products company of Eurofins Discovery, today announced the expansion of their CRO Certification Program for Bioassays with Catalent Biologics as a North American provider c

Castlight Health, Inc. (NYSE: CSLT) today announced the availability of its behavioral health solution to help employees easily access and navigate behavioral health support and resources amidst the COVID-19 pandemic

Modern Vascular, a pioneering medical group dedicated to preventing amputation through the treatment of peripheral artery disease (PAD) in the lower leg, today announced the expansion of its national footprint with the opening of its newest office in Fort Worth.

Echosens , a high-technology company offering the FibroScan family of products, today announces the release of its white paper authored by Dr. Reed Hogan, M.D., GI Associates (GIA) in Flowood, Mississippi, “ Understanding the Many Benefits of Comprehensive, Chronic Care Management (CCM) of Liver Dis

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m. London time (7 a.m. Eastern Daylight Time). The Company will release its second quarter 2020 results prior to the call. A live audiocast of the conference call will be available on the Investor Relations section of the LivaNova we

Diagnostic laboratories continue to be a crucial part of nationwide efforts to provide access to COVID-19 testing, which is critical to managing the pandemic.

Envoy Medical® Corporation , a hearing health company focused on providing innovative technologies across the hearing loss spectrum, today announced that its fully implanted Acclaim® cochlear implant was granted the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Unlike existing traditional

First dosing of Tacrolimus Inhalation Powder initiates development program for direct-to-lung delivery of a Thin Film Freezing dry-powder product for prevention of lung transplant rejection Phase 1 topline data indicates safety of single doses of Voriconazole Inhalation Powder up to 80 mg/dose in healthy subjects for direct-to-lung delivery of voriconazole for Invasive Pulmonary Aspergillosis AUSTIN, Texas--( BUSINESS WIRE )-- TFF Pharmaceutic

Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, today announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT®, have been published in Circulation, a peer-reviewed journal of the American Heart Association.

- Live on-air interview to feature Citius CEO on Tuesday, June 30th at 1:20pm ET - CEO to discuss potential use of Induced Mesenchymal Stem Cells (iMSCs) for the treatment of acute respiratory distress syndrome (ARDS) in patients with COVID-19 - Company to provide update about ongoing Phase 3 FDA Trial for Mino-Lok® [29-June-2020] CRANFORD, N.J. , J